| ID | 10041 |
| Vaccine Name | COVILO (BBIBP-CorV) |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Inactivated |
| Vaccine Status | Approved |
| Manufacturer | China National Biotec Group Company Limited |
| Year of Manufacturing | 2021 |
| Manufacturing Country | China |
| Age | 3 years and above |
| Dosage | 2 doses 21 days apart |
| Administration Route | Intramuscular |
| Adjuvant | Aluminum (aluminium hydroxide) |
| Target Strain | Inactivated SARS-CoV-2 virus |
| Description | Inactivated SARS-CoV-2 vaccine (Vero cell) is prepared by inoculating African green monkey kidney cells (Vero cell) with the SARS-CoV-2 HB02 strain |
| Approving Organisation | WHO, Caribbean Regulatory System Emergency Use Recommendation |
| Collaborating Organisation | Beijing Institute of Biotechnology |
| Other Countries | China, Bahrain, Egypt, Jordan, UAE, Hungary, Pakistan |
| Trade Name | NA |
| PMID | 33402220 |
| Clinical Trial ID | NCT04863638 |
| Reference Link | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/ |
| Additional Links | https://www.carpha.org/Portals/0/Documents/COVID-19%20Vaccine%20Updates/CARPHA%20COVID-19%20Vaccine%20Update%20047%20December%206%202021.pdf
|